Kalydeco Seen as Safe in Treating Young Children, Ages 1 to 2, in Phase 3 Trial, Vertex Reports
Kalydeco (ivacaftor) is safe and effective in 1- and 2-year-olds with cystic fibrosis (CF), Vertex Pharmaceuticals reported based on data from its ongoing Phase 3 clinical trial in infants and toddlers. The treatment’s safety was similar to that seen in studies of older children, the company said. Moreover,…